SCHEMBL265510

SCHEMBL265510

CCOc1cc(/C=N/NC(=O)c2ccccc2NC(=O)c2ccc(OC)c(OC)c2)ccc1O

nearest known ligand 0.71

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 9/20 0.71
MEN1 O00255 8/20 0.71
KDM4E B2RXH2 4/20 0.71
MAPT P10636 4/20 0.71
PKM P14618 2/20 0.71
HPGD P15428 2/20 0.71
SMN1; SMN2 Q16637 2/20 0.71
ALOX12 P18054 1/20 0.71
NPSR1 Q6W5P4 1/20 0.71
RAB9A P51151 4/20 0.67
NPC1 O15118 3/20 0.67
OPRK1 P41145 1/20 0.66
HTT P42858 1/20 0.66
TDP1 Q9NUW8 1/20 0.66
ALDH1A1 P00352 1/20 0.63
CRHBP P24387 1/20 0.59
CRHR2 Q13324 1/20 0.59
GAA P10253 4/20 0.55
ALPI P09923 1/20 0.55
ALPG P10696 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL265511 1.00 KMT2A (0.71) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL265897 0.93 MEN1 (0.82) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL265898 0.93 MEN1 (0.82) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL266236 0.89 NPC1 (0.74) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL266237 0.89 NPC1 (0.74) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL266708 0.87 NPC1 (0.72) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL266709 0.87 NPC1 (0.72) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL267010 0.86 PKM (0.81) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL267011 0.86 PKM (0.81) KMT2AMEN1KDM4EMAPTPKM
SCHEMBL266394 0.85 PKM (0.77) KMT2AMEN1KDM4EMAPTPKM

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-05-10 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-8134015-B2 Compound inhibiting in vivo phosphorous transport and medicine containing the same KYOWA HAKKO KIRIN CO., LTD. (JP) 2012-03-13 US disclosed
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same KIRIN BEER KABUSHIKI KAISHA (JP) 2006-09-28 US disclosed
EP-1614676-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME KIRIN BEER KABUSHIKI KAISHA (JP) 2006-01-11 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20060217426-A1 Compound inhibiting in vivo phosphorous transport and medicine containing the same SLC10A6, SLC7A1, SLC10A1 KMT2A 4564/4885MEN1 1194/4885KDM4E 4468/4885
US-20120115851-A1 COMPOUND INHIBITING IN VIVO PHOSPHORUS TRANSPORT AND MEDICINE CONTAINING THE SAME SLC34A1, SLC34A2, SLC20A2 KMT2A 4603/4885MEN1 1638/4885KDM4E 4535/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.